

# Nitrous oxide does not produce a clinically important sparing effect during closed-loop delivered propofol–remifentanyl anaesthesia guided by the bispectral index: a randomized multicentre study<sup>†</sup>

N. Liu<sup>1,2</sup>, M. Le Guen<sup>1</sup>, N. Boichut<sup>3</sup>, A. Genty<sup>4</sup>, T. Hérail<sup>5</sup>, D. Schmartz<sup>6</sup>, G. Khefif<sup>6</sup>, A. Landais<sup>7</sup>, J. J. Bussac<sup>8</sup>, A. Charneau<sup>9</sup>, J. Baars<sup>10</sup>, B. Rehberg<sup>11</sup>, S. Tricoche<sup>12</sup>, T. Chazot<sup>1</sup>, D. I. Sessler<sup>13</sup> and M. Fischler<sup>1\*</sup>

<sup>1</sup> Department of Anaesthesia, Hôpital Foch, Suresnes, France

<sup>2</sup> Outcomes Research Consortium, Cleveland, OH, USA

<sup>3</sup> Department of Anaesthesia, Centre Hospitalier Universitaire de Besançon, France

<sup>4</sup> Department of Anaesthesia, Clinique Saint Augustin, Bordeaux, France

<sup>5</sup> Department of Anaesthesia, Centre Hospitalier de Dreux, Dreux, France

<sup>6</sup> Department of Anaesthesia, ULB-Hôpital Erasme, Brussels, Belgium

<sup>7</sup> Department of Anaesthesia, Centre Hospitalier Victor Dupouy, Argenteuil, France

<sup>8</sup> Department of Anaesthesia, Institut Paoli Calmette, Marseille, France

<sup>9</sup> Department of Anaesthesia, Clinique de la Baie des Citrons, Nouméa, New Caledonia

<sup>10</sup> Department of Anaesthesia, Charité-Universitätsmedizin Berlin, Berlin, Germany

<sup>11</sup> Department of Anaesthesia, Hôpitaux Universitaires de Genève, Genève, Switzerland

<sup>12</sup> Department of Anaesthesia, Centre Hospitalier Universitaire de Tours, France

<sup>13</sup> Department of Outcomes Research, Cleveland Clinic, Cleveland, OH, USA

\* Corresponding author. E-mail: m.fischler@hopital-foch.org

## Editor's key points

- The hypothesis that N<sub>2</sub>O administration decreases the amount of propofol and remifentanyl required to maintain a specific bispectral index (BIS) was tested.
- N<sub>2</sub>O did not reduce propofol and remifentanyl requirements in men during BIS-guided anaesthesia.
- N<sub>2</sub>O has a non-clinically significant sparing effect on propofol and remifentanyl in women.

**Background.** Nitrous oxide (N<sub>2</sub>O) offers both hypnotic and analgesic characteristics. We therefore tested the hypothesis that N<sub>2</sub>O administration decreases the amount of propofol and remifentanyl given by a closed-loop automated controller to maintain a similar bispectral index (BIS).

**Methods.** In a randomized multicentre double-blind study, patients undergoing elective surgery were randomly assigned to breathe 60% inspired N<sub>2</sub>O (N<sub>2</sub>O group) or 40% oxygen (AIR group). Anaesthesia depth was evaluated by the proportion of time where BIS was within the range of 40–60 (BIS<sub>40–60</sub>). The primary outcomes were propofol and remifentanyl consumption, with reductions of 20% in either being considered clinically important.

**Results.** A total of 302 patients were randomized to the N<sub>2</sub>O group and 299 to the AIR group. At similar BIS<sub>40–60</sub> [79 (67–86)% vs 76 (65–85)%], N<sub>2</sub>O slightly decreased propofol consumption [4.5 (3.7–5.5) vs 4.8 (4.0–5.9) mg kg<sup>-1</sup> h<sup>-1</sup>, *P*=0.032], but not remifentanyl consumption [0.17 (0.12–0.23) vs 0.18 (0.14–0.24) µg kg<sup>-1</sup> min<sup>-1</sup>]. For the subgroups of men, at similar BIS<sub>40–60</sub> [80 (72–88)% vs 80 (70–87)%], propofol [4.2 (3.4–5.3) vs 4.4 (3.6–5.4) mg kg<sup>-1</sup> h<sup>-1</sup>] and remifentanyl [0.19 (0.13–0.25) vs 0.18 (0.15–0.23) µg kg<sup>-1</sup> min<sup>-1</sup>] consumptions were similar in the N<sub>2</sub>O vs AIR group, respectively. For the subgroups of women, at similar BIS<sub>40–60</sub> [76 (64–84)% vs 72 (62–82)%], propofol [4.7 (4.0–5.8) vs 5.3 (4.5–6.6) mg kg<sup>-1</sup> h<sup>-1</sup>, *P*=0.004] and remifentanyl [0.18 (0.13–0.25) vs 0.20 (0.15–0.27) µg kg<sup>-1</sup> min<sup>-1</sup>, *P*=0.029] consumptions decreased with the co-administration of N<sub>2</sub>O.

**Conclusions.** With automated drug administration titrated to comparable BIS, N<sub>2</sub>O only slightly reduced propofol consumption and did not reduce remifentanyl consumption. There was a minor gender dependence, but not by a clinically important amount.

**Clinical trial registration.** This study was registered at ClinicalTrials.gov, number NCT00547209.

**Keywords:** bispectral index monitor; closed-loop; nitrous oxide; propofol; remifentanyl

Accepted for publication: 22 August 2013

<sup>†</sup>Presented in part as an oral presentation at the annual meeting of the Society for Technology in Anesthesia January 13, 2011, in Las Vegas, NE, USA.

Nitrous oxide ( $\text{N}_2\text{O}$ ) is a reliable short-acting, well-tolerated, and inexpensive anaesthetic gas.  $\text{N}_2\text{O}$  is not potent enough to be used as a sole agent, but is commonly used as an adjunct to balance volatile or i.v. general anaesthesia; it has a hypnotic action mediated by the *N*-methyl-D-aspartate subtype of glutamate receptors. Moreover,  $\text{N}_2\text{O}$  has an analgesic effect because it acts as a supraspinal opioid agonist in the periaqueductal grey matter and activates noradrenergic neurones in the locus coeruleus which project to  $\alpha_1$  and  $\alpha_2$  adrenoreceptors within the dorsal horn of the spinal cord.<sup>1</sup>

The most obvious advantage of adding  $\text{N}_2\text{O}$  to an anaesthetic regimen is a reduction in hypnotic and opioid consumption. For example, the use of  $\text{N}_2\text{O}$  reduced propofol induction dose by 44%,<sup>2</sup> reduced the propofol concentration required to avoid a response to a surgical stimuli by 30%,<sup>3</sup> and reduced propofol consumption during general anaesthesia maintenance by 15–25%.<sup>4, 5</sup> Other studies report that adding  $\text{N}_2\text{O}$  produces a clinical benefit similar to a remifentanyl infusion of  $0.085 \mu\text{g kg}^{-1} \text{min}^{-1}$  during desflurane anaesthesia guided by the BIS<sup>6</sup> or  $0.17 \mu\text{g kg}^{-1} \text{min}^{-1}$  during isoflurane inhalation.<sup>7</sup> A limitation of these studies is that propofol administration was adjusted manually by unblinded investigators in accordance with haemodynamic and clinical criteria.<sup>3–7</sup>

An alternative to haemodynamic and clinical criteria for drug administration during general anaesthesia is titration to electrocortical activity measured by the bispectral index (BIS) monitor (Covidien, Dublin, Ireland).<sup>8</sup> There are reports showing that, in the absence of noxious stimuli, BIS is not affected by  $\text{N}_2\text{O}$  inhalation in volunteers<sup>9</sup> or patients.<sup>10–13</sup> Moreover, several studies showed a poor relationship between clinical sedation scales and the BIS during sedation of volunteers<sup>14</sup> and adult<sup>15, 16</sup> or paediatric<sup>17</sup> patients. However,  $\text{N}_2\text{O}$  as an anaesthetic adjuvant modifies electrocortical activation during surgery<sup>18</sup> and the response to noxious stimuli such as laryngoscopy during volatile anaesthesia.<sup>19</sup> Furthermore, electrocortical activity is a function of anaesthetic depth during surgery<sup>20</sup> and in response to noxious stimuli.<sup>19, 21, 22</sup> There is only slight evidence that  $\text{N}_2\text{O}$  does not affect BIS values during maintenance of general anaesthesia. Studies related to the influence of  $\text{N}_2\text{O}$  on BIS values were performed on volunteers<sup>9</sup> during induction<sup>10</sup> and the number of patients studied during surgery was limited.<sup>11–13</sup> The extent to which  $\text{N}_2\text{O}$  spares i.v. anaesthetics or modifies BIS values during maintenance of general anaesthesia thus remains unclear.

We have developed a closed-loop controller allowing automated titration of propofol and remifentanyl solely guided by the BIS. An automated controller of drug delivery is an unbiased assessment of anaesthetic requirements when an adjunct is used.<sup>23</sup> We used this objective system in a randomized controlled multicentre trial to determine the sparing effect of 60%  $\text{N}_2\text{O}$  on propofol or remifentanyl consumption during maintenance of general anaesthesia. Specifically, we tested the primary hypothesis that  $\text{N}_2\text{O}$  administration decreases the amount of propofol and remifentanyl given by our closed-loop controller to maintain a similar BIS index. Our secondary hypothesis, added at the request of the

German Ethics Committee, was that there is an interaction between gender and the drug-sparing effect of  $\text{N}_2\text{O}$ .

## Methods

### Study population

Our prospective multicentre randomized double-blind clinical trial was approved by the Ethics Committees of the participating French (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale, Hôpital A. Paré, Boulogne Billancourt, France), Belgian (Comité d'Éthique hospitalo-facultaire Erasme-ULB, Brussels, Belgium), and German universities (Ethikkommission der Charité-Universitätsmedizin, Berlin, Germany). It was also approved by the French national regulatory office (Agence Française de Sécurité Sanitaire des Produits de Santé). This study was registered at ClinicalTrials.gov, number NCT00547209.

Written informed consent was obtained during the preoperative visit performed by the investigators. Patients undergoing elective surgery (vascular, general, orthopaedic, gynaecological, urological, otolaryngological) requiring general anaesthesia without combined regional/general anaesthesia expected to last more than 60 min and requiring tracheal intubation were enrolled at 10 university, general, or private hospitals: Hôpital Foch (Suresnes), Centre Hospitalier Victor Dupouy (Argenteuil), Centre Hospitalo-Universitaire of Besançon and Tours, Clinique Saint Augustin (Bordeaux), La Baie des Citrons (Nouméa) New Caledonia, ULB-Erasme (Brussels) Belgium, and Charité-Universitätsmedizin Berlin (Berlin) Germany. Patients were aged 18–80 yr and ASA physical status I–IV. Exclusion criteria included cranial procedures, psychiatric illness, supraspinal neurological disorders, and patients equipped with a pacemaker. Moreover, patients undergoing thoracic or cardiac surgery were excluded due to possible occurrence of hypoxaemia or gas embolism, respectively.

### Procedures

All patients received a propofol and remifentanyl infusion controlled by our automated closed-loop system during induction and maintenance of general anaesthesia.<sup>8</sup> All investigators received a full day of training in the use of the automated controller at the Hôpital Foch, Suresnes, France.

On arrival in the theatre, a dedicated i.v. cannula was inserted, routine monitoring commenced including temperature. Neuromuscular function at the adductor pollicis was monitored after loss of consciousness. A BIS electrode (Zipprep, Covidien) was positioned on the patient's forehead and connected to either an A-2000 XP (version 3.11) BIS monitor or a BIS M-Module (GE-Healthcare S/5™, Helsinki, Finland).


The controller<sup>8</sup> was implemented using Infusion Toolbox 95<sup>®</sup> version 4.11 software<sup>24</sup> which served as a platform: (i) to calculate effect-site concentrations of propofol and remifentanyl using the pharmacokinetic population of Schnider and colleagues<sup>25</sup> and Minto and colleagues<sup>26</sup> for propofol and remifentanyl, respectively; (ii) to display these calculated effect-site concentration estimates in real time; (iii) to provide a user

interface that permits entry of patient characteristic data (sex, age, weight, and height) and modification of upper and lower limits of drug concentrations; (iv) to control the propofol and remifentanyl infusion pumps (Asena GH<sup>®</sup>, Alaris Medical, Hampshire, UK); and (v) recording BIS, calculated effect-site concentrations, and haemodynamic data when an AS/5<sup>™</sup> monitor was used. In both groups, the investigator chose the initial propofol effect-site target concentration according to his/her clinical judgement and the controller fixed the first remifentanyl effect-site target concentration. In both groups, patients received total i.v. anaesthesia in target-controlled infusion mode using the automated controller of propofol and remifentanyl. Patients received a neuromuscular blocking agent to facilitate tracheal intubation.

The controller has a cascade structure including a dual proportional-integral-derivative algorithm and a target-controlled infusion system for the administration of i.v. anaesthetics. The controller uses the parameters from the BIS monitor if the signal quality index is more than 50%. The controller measures the electromyographic activity, the percentage of burst suppression ratio (SR), and calculates the BIS<sub>error</sub> or the difference between the set point of 50 and the actual measured BIS value. If the BIS<sub>error</sub> is different from 0, the controller determines a new propofol, remifentanyl, or both concentrations. The controller increases or decreases the drug concentration according to the BIS<sub>error</sub> sign. The error size determines which drug will be modified: if the BIS<sub>error</sub> is small, only the remifentanyl is changed; if the BIS<sub>error</sub> is higher than a threshold, the two drug concentrations are changed. The minimal interval between two consecutive controls is set

equal to the time to peak effect of each drug; this time interval is shorter for remifentanyl<sup>26</sup> than for propofol,<sup>25</sup> thus remifentanyl modifications are made more frequently. The feed-forward term gives the rate of change in the error and amplifies every 5 s the correction of the drugs when a measured BIS value is > 60. The interaction rule between propofol and remifentanyl is as follows: if the controller successively increases the remifentanyl concentration more than three times, then the propofol concentration is increased. A detailed description of the controller has been provided in a previous controlled study.<sup>8</sup> In the current study, the controller was identical for the thresholds, rules, propofol gain constants, and lower and upper limits of propofol (1.3 and 5 µg ml<sup>-1</sup>) or remifentanyl (3 and 12 ng ml<sup>-1</sup>) of the previous controller. Only the values of gain constants for the remifentanyl were decreased by 15%. Throughout the procedure, the investigator could adjust the lower or the upper limits of propofol remifentanyl when the BIS decreased to and remained under 40.

Patients were allocated into two groups in a 1:1 ratio: the AIR group in which the lungs were mechanically ventilated with 40% inspired oxygen fraction after tracheal intubation or the N<sub>2</sub>O group in which the lungs were mechanically ventilated using a mixture of 40% inspired oxygen fraction and 60% of inspired N<sub>2</sub>O after tracheal intubation. Treatments were segregated into blocks of 10 at each participating centre, and randomization was determined using an online random number generator just before anaesthesia induction. Other than administration of the study drugs, patient management was based on current standards of care. No specific recommendations were given for the treatment of haemodynamic



abnormalities and for the use of a neuromuscular blocking agent. Approximately 45 min before the presumed end of surgery, i.v. analgesics were given to provide postoperative pain relief. Morphine, paracetamol, nefopam, or non-steroidal anti-inflammatory drugs were given at the discretion of the physician. In both groups, propofol and remifentanyl were stopped simultaneously upon completion of surgery and all patients were ventilated with 100% oxygen before tracheal extubation.


The primary outcomes were propofol or remifentanyl consumption during maintenance of general anaesthesia. Consumption was defined by drug requirement between the start of mechanical ventilation and the end of drug infusion. Secondary outcomes included the percentage of data points with adequate anaesthesia, defined as BIS between 40 and 60 (BIS<sub>40-60</sub>), deep anaesthesia (BIS<sub><40</sub>), and light anaesthesia (BIS<sub>>60</sub>). Excessive anaesthesia was defined as the occurrence of SR with SR >10% lasting at least 1 min.<sup>27</sup> The number of somatic events (i.e. movement, grimacing) was recorded. Recall of intraoperative events was determined by a standardized interview performed in the post-anaesthesia care unit

and on the second or third postoperative day.<sup>28</sup> An analysis related to the gender was performed upon request by the German ethical committee.

### Statistical analyses

In a previous study during maintenance of general anaesthesia, propofol and remifentanyl consumption were 4.7 (1.6) mg kg<sup>-1</sup> h<sup>-1</sup> and 0.22 (0.07) µg kg<sup>-1</sup> min<sup>-1</sup> using the dual-loop controller.<sup>8</sup> We anticipated that N<sub>2</sub>O administration would reduce propofol or remifentanyl consumption by at least 20% and thus estimated that a total of 144 patients per group would provide a 95% power for a two-sided  $\alpha$ -error of 1%. To provide adequate power for the gender interaction analysis, we planned to recruit 680 patients under the assumption that some would be excluded for various reasons.

Categorical variables, expressed as numbers and frequencies, were compared using Fisher's exact test as appropriate. Continuous variables were described as the median and inter-quartile range (IQR) and compared using the Mann-Whitney U-test. The statistical analysis was performed in the overall



**Fig 2** Examples for the interpretation of automated control of propofol and remifentanyl guided by the BIS. (A) Ninety-four per cent of anaesthesia maintenance the BIS was adequate or in the range 40 and 60 (BIS<sub>40-60</sub>) or pink area in the upper figure. The propofol and remifentanyl lower limits were never reached. We can conclude that propofol and remifentanyl titrations were performed correctly. (B) The BIS<sub>40-60</sub> = 26%, the pink area represents a period of too deep anaesthesia, the lower limits of propofol (1.3 µg ml<sup>-1</sup>) and remifentanyl (3 ng ml<sup>-1</sup>) were reached and the controller could not decrease the concentrations. This case was excluded from the analysis. (C) The BIS<sub>40-60</sub> = 37%, the pink area represents a period of too deep anaesthesia, the lower propofol and remifentanyl limits were increased (2 µg ml<sup>-1</sup> and 4 ng ml<sup>-1</sup>, respectively) by the investigator and the controller could not decrease the concentrations. This case was excluded from the analysis. Upper figure: BIS value. Lower figure: effect-site concentration = calculated effect-site concentration of propofol (µg ml<sup>-1</sup>), or remifentanyl (ng ml<sup>-1</sup>); green dashed line, propofol and blue thick line, remifentanyl.



population and by gender after an analysis of variance test to determine the interaction between propofol or remifentanyl and gender. Probability values of  $<0.05$  using two-tailed tests were considered statistically significant. Data analysis was performed using IBM-SPSS® version 20 (IBM-SPSS Science, Inc., Chicago, IL, USA).

## Results

Among 686 patients who were approached, 672 were recruited between January 2008 and June 2009. Usable data were obtained from 299 patients in the AIR group and 302 patients in the N<sub>2</sub>O group (Fig. 1). Different examples for the interpretation of automated control are presented in Figure 2. Baseline characteristics were similar as a function of N<sub>2</sub>O administration and gender (Table 1). One-third of subjects took at least one cardiovascular medication before operation. The median BIS values from induction to propofol and remifentanyl discontinuation are presented in Figure 3. During induction, propofol requirements were similar with N<sub>2</sub>O [ $1.1$  ( $0.7$ – $1.4$ ) mg kg<sup>-1</sup>] and AIR [ $1.0$  ( $0.7$ – $1.4$ ) mg kg<sup>-1</sup>,  $P=0.51$ ]; remifentanyl requirements were also similar with N<sub>2</sub>O [ $1.8$  ( $1.4$ – $2.8$ ) µg kg<sup>-1</sup>] and AIR [ $1.8$  ( $1.4$ – $2.9$ ) µg kg<sup>-1</sup>,  $P=0.48$ ].

The lower limit of propofol was decreased more frequently in the N<sub>2</sub>O group than in the AIR group (51% vs 34% of patients,  $P<0.0001$ ). The lower limit of remifentanyl was decreased in

similar occurrence between the two groups (22% vs 17% of patients,  $P=0.18$  N<sub>2</sub>O vs AIR respectively). N<sub>2</sub>O administration significantly decreased propofol requirement by 6%, although hypnotic effect as determined by the percentage of BIS<sub>40–60</sub> or procedure duration was similar (Fig. 4, Table 2).

The subgroups of women, N<sub>2</sub>O<sub>women</sub> ( $n=145$ ) and Air<sub>women</sub> ( $n=145$ ), were well balanced with respect to demography, morphometrics, and surgical procedure (Table 1). There was a significant interaction between gender and anaesthetic: N<sub>2</sub>O decreased propofol requirements by 11% ( $P=0.004$ ) and remifentanyl requirements by 14% ( $P=0.029$ ) in women, but had almost no effect in men (Table 3, Fig. 4). Women, but not men, were more likely to experience light anaesthesia (BIS<sub>>60</sub>) during AIR than nitrous oxide administration (Table 2). However, in the subgroup of men, N<sub>2</sub>O decreased the occurrence of movements and hypertensive episodes with antihypertensive therapy (Table 2). No cases of awareness with recall were reported.


## Discussion

Automated administration of anaesthetic drugs is objective and, therefore, an appropriate method for evaluating the contribution of anaesthetic adjuvants since clinician bias is eliminated. This approach has consequently been used, for example, to determine the sparing effect of N<sub>2</sub>O on the rocuronium requirement<sup>23</sup> and the sparing effect of remifentanyl on propofol.<sup>29</sup> The closed-loop approach that we used thus compares favourably with previous studies in which the sparing effects of N<sub>2</sub>O were evaluated by unblinded protocol and depth of hypnosis or analgesia were evaluated by haemodynamic criteria.<sup>3–7</sup> Haemodynamic responses, in particular, are poor indicators of hypnotic depth and influenced by painful stimulation, to say nothing of chronic hypertension and various treatments, blood loss, fluid administration, vasopressor use, heart failure, arrhythmia, and manipulation of great vessels. Our primary result is that in our study population, which was roughly balanced among men and women, N<sub>2</sub>O reduced propofol consumption by only 6%. While statistically significant, this small reduction is not clinically important.

Gender differences have been reported for various aspects of anaesthesia care, including postoperative nausea and vomiting<sup>30</sup> or postoperative pain intensity.<sup>31</sup> Women require more propofol than men during maintenance of general anaesthesia<sup>32</sup> and wake up faster.<sup>33–35</sup> Curiously, gender differences have yet to be reported for N<sub>2</sub>O, although they may explain apparent discrepancies in reported electrophysiological effects of N<sub>2</sub>O. For example, N<sub>2</sub>O alone increased the  $\beta$  and  $\theta$  or excitatory electrocortical activity in a volunteer study in which the sex ratio was well balanced.<sup>9</sup> In contrast, N<sub>2</sub>O increased  $\delta$  activity or central inhibitory action in a surgical patient study in which 14 of 15 patients were female.<sup>18</sup> Our results show that the effect of nitrous oxide on anaesthetic requirement differed as a function of gender, with nearly all the observed sparing being in women. Furthermore, N<sub>2</sub>O decreased light anaesthesia or BIS<sub>>60</sub> only in women. The interaction between N<sub>2</sub>O and drug sparing by gender was

**Table 1** Characteristics of patients at entry. Data presented as medians (IQR), or number (%). N<sub>2</sub>O, patients were ventilated with 60% of nitrous oxide; AIR, patients were ventilated with 40% of oxygen. Preoperative cardiovascular treatment including  $\beta$ -blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, or diuretics

	N <sub>2</sub> O	Air
Number of patients	302	299
Male	157	154
Female	145	145
Age (yr)	58 (46–67)	58 (44–71)
Male	60 (53–68)	61 (50–71)
Female	54 (44–65)	55 (41–69)
Height (cm)	170 (161–175)	170 (161–175)
Male	174 (170–180)	174 (170–178)
Female	163 (159–168)	162 (157–167)
Weight (kg)	72 (63–80)	73 (62–84)
Male	77 (69–83)	79 (71–88)
Female	66 (59–79)	65 (57–77)
ASA physical status III and IV	46 (15)	58 (19)
Male	29 (18)	39 (25)
Female	17 (12)	19 (13)
Cardiovascular treatment	87 (29)	101 (34)
Male	49 (31)	63 (41)
Female	38 (26)	38 (26)
Major surgery	115 (39)	128 (44)
Male	79 (51)	80 (53)
Female	36 (25)	48 (34)




**Fig 3** BIS values from induction to the discontinuation of propofol and remifentanyl for all, male and female patients. Data are given as median values (blue thick line) with 10th and 90th percentiles (green fine line) with a moving average filter of 1 min duration for graphical representation. N<sub>2</sub>O, patients were ventilated with 60% of nitrous oxide; AIR, patients were ventilated with 40% of oxygen.

statistically significant (Table 3); however, the effect is probably not clinically relevant even in women. For example, the propofol-sparing effect of 60% inspired N<sub>2</sub>O is only 39 mg h<sup>-1</sup> and the remifentanyl-sparing effect is only 78 µg h<sup>-1</sup> in a woman weighing 65 kg. A study including stratification by gender is probably necessary to give a definitive conclusion of this difference. However, to detect a difference of 12% propofol consumption with a two-sided  $\alpha$ -error of 5% and a power of 80%, the minimum effect size of interest is 112 patients. In the current study, we included more than 145 patients per group (Table 1), thus power was adequate, and the decrease in propofol consumption simply too small to be clinically important.

Intraoperative movement is common (i.e. 60%) during alfentanil and propofol anaesthesia, and the incidence is halved by N<sub>2</sub>O administration.<sup>36</sup> Intraoperative movement possibly results more from inadequate analgesia than inadequate hypnosis. N<sub>2</sub>O is analgesic; but at least in animals, its analgesic action is to some degree dissociated from immobility.<sup>37</sup> We found that N<sub>2</sub>O administration reduced movement and hypertension only in men and this spinal action may be clinically useful (Table 2). Finally, our study reported a supraspinal activity of N<sub>2</sub>O in women reflected by the decrease in drug requirements given by the controller, and a spinal activity of N<sub>2</sub>O in men suggested by the decreased incidence of

hypertension and movements without the decrease in drug requirement related to the absence of cortical activity changes.

Patients included in the current study underwent a variety of surgical procedures, in different centres, with different surgeons, which might have led to different noxious stimuli levels. Unfortunately, we did not record, during the different surgical procedures, the periods with or without noxious stimulation for all patients. Moreover, we lack specific and robust monitors for the quantification of noxious stimuli intensity. The sparing effect of N<sub>2</sub>O on anaesthetic requirements is related to the intensity of noxious stimuli<sup>19 22</sup> and mediated by an anti-nociceptive action such as provided by lidocaine.<sup>38</sup> Probably, N<sub>2</sub>O is more effective for open rather than laparoscopic procedures, but the difference needs to be clinically relevant during propofol–remifentanyl anaesthesia.<sup>39</sup> Indeed, to obtain a desired BIS value, there are several combinations of propofol–remifentanyl ratios. But, in both groups, we used the same controller, with the same reproducible titration method for propofol and remifentanyl and the results were related to gain constants of the controller. Certainly, the results would be different with another controller gain constant, with a single closed loop of propofol with a continuous and fixed infusion at different targets of remifentanyl, or with a continuous fixed infusion of propofol at different targets associated with a single remifentanyl closed-loop controller guided by BIS.



**Fig 4** Histogram of propofol and remifentanyl consumption. Distribution of propofol (left figures) and remifentanyl (right figures) consumptions in all patients and by gender; P-values were reported for each figure. N<sub>2</sub>O, patients were ventilated with 60% of nitrous oxide; AIR, patients were ventilated with 40% of oxygen. Blue filled histograms represent the N<sub>2</sub>O group and green striped histograms represent the AIR group. Normal distribution curve for the N<sub>2</sub>O (pink dashed line) and AIR (orange solid line) groups.

**Table 2** Comparison of anaesthetic procedures during the maintenance phase. Data presented as medians (IQR), or number (%). N<sub>2</sub>O, patients were ventilated with 60% of nitrous oxide; AIR, patients were ventilated with 40% of oxygen. Duration, duration of anaesthesia; SR, suppression ratio; occurrence of SR was defined as SR value > 10% lasting more than 1 min. BIS, bispectral index. BIS<sub>40–60</sub>, percentage of time in which the BIS value was between 40 and 60 during the maintenance. BIS<sub><40</sub>, percentage of time in which the BIS value was below a value of 40. BIS<sub>>60</sub>, percentage of time in which the BIS value was greater than a value of 60

	N <sub>2</sub> O	Air	P-value
Number of patients	302	299	
Male	157	154	
Female	145	145	
Duration (min)	129 (83–187)	125 (84–200)	0.83
Male	143 (95–222)	139 (91–225)	0.70
Female	107 (80–148)	109 (70–165)	0.37
BIS <sub>40–60</sub> (%)	79 (67–86)	76 (65–85)	0.30
Male	80 (72–88)	80 (70–87)	0.85
Female	76 (64–84)	72 (62–82)	0.20
BIS <sub>&lt;40</sub> (%)	15 (9–23)	16 (10–24)	0.71
Male	15 (9–23)	16 (10–24)	0.98
Female	21 (13–31)	23 (14–32)	0.58
BIS <sub>&gt;60</sub> (%)	3 (1–5)	4 (2–6)	0.001
Male	2 (1–5)	3 (2–5)	0.69
Female	3 (1–5)	4 (2–7)	0.005
Occurrence of SR	59 (20)	54 (18)	0.75
Male	37 (24)	32 (21)	0.69
Female	22 (15)	22 (15)	1
Propofol (mg kg <sup>-1</sup> h <sup>-1</sup> )	4.5 (3.7–5.5)	4.8 (4.0–5.9)	0.032
Male	4.2 (3.4–5.3)	4.4 (3.6–5.4)	0.92
Female	4.7 (4.0–5.8)	5.3 (4.5–6.6)	0.004
Remifentanyl (μg kg <sup>-1</sup> min <sup>-1</sup> )	0.17 (0.12–0.23)	0.18 (0.14–0.24)	0.21
Male	0.19 (0.13–0.25)	0.18 (0.15–0.23)	0.58
Female	0.18 (0.13–0.25)	0.20 (0.15–0.27)	0.029
Movement	18 (6)	40 (13)	0.004
Male	6 (4)	21 (14)	0.005
Female	12 (8)	19 (13)	0.26
Anti-hypertensive therapy	21 (7)	46 (15)	0.005
Male	13 (8)	28 (18)	0.012
Female	8 (6)	18 (12)	0.063
Neuromuscular blockers	129 (43)	147 (49)	0.34
Male	73 (46)	85 (55)	0.43
Female	56 (39)	62 (43)	0.66
Ephedrine bolus	109 (36)	96 (32)	0.51
Male	58 (37)	47 (31)	0.43
Female	51 (35)	49 (34)	0.91

**Table 3** Interaction of gender with propofol and remifentanyl consumption. Two-factors analysis of variance with interaction. One fixed factor was the treatment (group) and one random factor gender. DF, degree of freedom

	Source	DF	F-ratio	P-value
Propofol	Group	1	1.13	0.48
	Gender	1	56.3	<0.0002
Remifentanyl	Group	1	1.11	0.48
	Gender	1	37.5	<0.0001

However, the sparing effect of N<sub>2</sub>O would probably be <20% and not clinically relevant. Another limitation of our approach is that N<sub>2</sub>O causes a degree of sympathetic activation which activates electroencephalographic signals after noxious stimuli.<sup>21</sup> A consequence is that N<sub>2</sub>O decreases BIS less than would be expected based on its MAC.<sup>9</sup> A closed-loop system controlled to another anaesthetic measure of anaesthesia depth might well have identified a greater drug-sparing effect of N<sub>2</sub>O. The difficulty, of course, is that there are few well-validated measures of hypnotic effect that do not depend on the electroencephalogram. We only evaluated the sparing



effect on propofol and remifentanyl consumption and not post-operative morphine requirements. Specific studies are necessary to determine if N<sub>2</sub>O can prevent hyperalgesia related to remifentanyl titrate by the BIS.<sup>40</sup>

In summary, N<sub>2</sub>O did not reduce propofol and remifentanyl requirements in men during BIS-guided anaesthesia. In contrast, N<sub>2</sub>O significantly spares propofol and remifentanyl in women—although the magnitude of the reduction is unlikely to prove clinically important. Adding nitrous oxide to BIS-guided closed-loop i.v. anaesthesia thus appears to provide little benefit.

## Authors' contributions

N.L.: study design, conduct of the study, data analysis, and manuscript preparation. M.L.G.: conduct of the study, data analysis, and manuscript preparation. N.B.: conduct of the study. A.G.: conduct of the study. T.H.: conduct of the study. D.S.: conduct of the study. G.K.: conduct of the study. A.L.: conduct of the study. J.J.B.: conduct of the study. A.C.: conduct of the study. J.B.: conduct of the study. B.R.: conduct of the study and manuscript preparation. S.T.: conduct of the study. T.C.: study design, conduct of the study, and data analysis. D.I.S.: manuscript preparation. M.F.: study design and manuscript preparation.

## Declaration of interest

Support was provided by the Service d'Anesthésie, Hôpital Foch, Suresnes, France, Vaincre la Mucoviscidose (Paris, France), and by Alaris Medical (Hampshire, UK) who loaned the Asena GH infusion pumps to the study. Hôpital Foch, N.L., and T.C. have a patent in France for the gain constants in the control algorithm (No. BFF08P669, Institut National de la Propriété Industrielle, France). None of the other authors has a personal financial interest in this research.

## References

- Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. *Anesthesiology* 2008; **109**: 707–22
- Ng JM, Hwang NC. Inhaling nitrous oxide reduces the induction dose requirements of propofol. *Anesth Analg* 2000; **90**: 1213–6
- Davidson JA, Macleod AD, Howie JC, White M, Kenny GN. Effective concentration 50 for propofol with and without 67% nitrous oxide. *Acta Anaesthesiol Scand* 1993; **37**: 458–64
- Sukhani R, Lurie J, Jabamoni R. Propofol for ambulatory gynecologic laparoscopy: does omission of nitrous oxide alter post-operative emetic sequelae and recovery? *Anesth Analg* 1994; **78**: 831–5
- Arellano RJ, Pole ML, Rafuse SE, et al. Omission of nitrous oxide from a propofol-based anesthetic does not affect the recovery of women undergoing outpatient gynecologic surgery. *Anesthesiology* 2000; **93**: 332–9
- Mathews DM, Gaba V, Zaku B, Neuman GG. Can remifentanyl replace nitrous oxide during anesthesia for ambulatory orthopedic surgery with desflurane and fentanyl? *Anesth Analg* 2008; **106**: 101–8
- Lee LH, Irwin MG, Lui SK. Intraoperative remifentanyl infusion does not increase postoperative opioid consumption compared with 70% nitrous oxide. *Anesthesiology* 2005; **102**: 398–402
- Liu N, Chazot T, Hamada S, et al. Closed-loop coadministration of propofol and remifentanyl guided by bispectral index: a randomized multicenter study. *Anesth Analg* 2011; **112**: 546–57
- Rampil IJ, Kim JS, Lenhardt R, Negishi C, Sessler DI. Bispectral EEG index during nitrous oxide administration. *Anesthesiology* 1998; **89**: 671–7
- Barr G, Jakobsson JG, Owall A, Anderson RE. Nitrous oxide does not alter bispectral index: study with nitrous oxide as sole agent and as an adjunct to i.v. anaesthesia. *Br J Anaesth* 1999; **82**: 827–30
- Ozcan MS, Ozcan MD, Khan QS, Thompson DM, Chetty PK. Does nitrous oxide affect bispectral index and state entropy when added to a propofol versus sevoflurane anesthetic? *J Neurosurg Anesthesiol* 2010; **22**: 309–15
- Soto RG, Smith RA, Zaccaria AL, Miguel RV. The effect of addition of nitrous oxide to a sevoflurane anesthetic on BIS, PSI, and entropy. *J Clin Monit Comput* 2006; **20**: 145–50
- Eilers H, Larson MD. The effect of ketamine and nitrous oxide on the human pupillary light reflex during general anesthesia. *Auton Neurosci* 2010; **152**: 108–14
- Hall DL, Weaver J, Ganzberg S, Rashid R, Wilson S. Bispectral EEG index monitoring of high-dose nitrous oxide and low-dose sevoflurane sedation. *Anesth Prog* 2002; **49**: 56–62
- Karalapillai D, Leslie K, Umranikar A, Bjorksten AR. Nitrous oxide and anesthetic requirement for loss of response to command during propofol anesthesia. *Anesth Analg* 2006; **102**: 1088–93
- Park KS, Hur EJ, Han KW, Kil HY, Han TH. Bispectral index does not correlate with observer assessment of alertness and sedation scores during 0.5% bupivacaine epidural anesthesia with nitrous oxide sedation. *Anesth Analg* 2006; **103**: 385–9
- Isik B, Tuzuner T, Tezkircioglu M, Oztas N. Nitrous oxide sedation and bispectral index. *Eur J Dent* 2007; **1**: 240–5
- Avramov MN, Shingu K, Mori K. Progressive changes in electroencephalographic responses to nitrous oxide in humans: a possible acute drug tolerance. *Anesth Analg* 1990; **70**: 369–74
- Oda Y, Tanaka K, Matsuura T, Hase I, Nishikawa K, Asada A. Nitrous oxide induces paradoxical electroencephalographic changes after tracheal intubation during isoflurane and sevoflurane anesthesia. *Anesth Analg* 2006; **102**: 1094–102
- Henrie JR, Parkhouse J, Bickford RG. Alteration of human consciousness by nitrous oxide as assessed electro-encephalography and psychological tests. *Anesthesiology* 1961; **22**: 247–59
- Coste C, Guignard B, Menigaux C, Chauvin M. Nitrous oxide prevents movement during orotracheal intubation without affecting BIS value. *Anesth Analg* 2000; **91**: 130–5
- Hans P, Bonhomme V, Benmansour H, Dewandre PY, Brichant JF, Lamy M. Effect of nitrous oxide on the bispectral index and the 95% spectral edge frequency of the electroencephalogram during surgery. *Anaesthesia* 2001; **56**: 999–1002
- Illman H, Antila H, Olkkola KT. Quantitation of the effect of nitrous oxide on rocuronium infusion requirements using closed-loop feedback control. *Anesthesiology* 2008; **108**: 388–91
- Cantraine FR, Coussaert EJ. The first object oriented monitor for intravenous anesthesia. *J Clin Monit Comput* 2000; **16**: 3–10
- Schnider TW, Minto CF, Shafer SL, et al. The influence of age on propofol pharmacodynamics. *Anesthesiology* 1999; **90**: 1502–16
- Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanyl. I. Model development. *Anesthesiology* 1997; **86**: 10–23

- 27 Besch G, Liu N, Samain E, et al. Occurrence of and risk factors for electroencephalogram burst suppression during propofol–remifentanyl anaesthesia. *Br J Anaesth* 2011; **107**: 749–56
- 28 Leclerc C, Gerard JL, Bricard H. Intraoperative memory. A study of its incidence in general anesthesia in 326 patients. *Ann Fr Anesth Reanim* 2001; **20**: 592–9
- 29 Milne SE, Kenny GN, Schraag S. Propofol sparing effect of remifentanyl using closed-loop anaesthesia. *Br J Anaesth* 2003; **90**: 623–9
- 30 Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. *N Engl J Med* 2004; **350**: 2441–51
- 31 Cepeda MS, Carr DB. Women experience more pain and require more morphine than men to achieve a similar degree of analgesia. *Anesth Analg* 2003; **97**: 1464–8
- 32 Kreuer S, Biedler A, Larsen R, Altmann S, Wilhelm W. Narcotrend monitoring allows faster emergence and a reduction of drug consumption in propofol–remifentanyl anesthesia. *Anesthesiology* 2003; **99**: 34–41
- 33 Gan TJ, Glass PS, Sigl J, et al. Women emerge from general anesthesia with propofol/alfentanil/nitrous oxide faster than men. *Anesthesiology* 1999; **90**: 1283–7
- 34 Buchanan FF, Myles PS, Cicuttini F. Effect of patient sex on general anaesthesia and recovery. *Br J Anaesth* 2011; **106**: 832–9
- 35 Hoymork SC, Raeder J. Why do women wake up faster than men from propofol anaesthesia? *Br J Anaesth* 2005; **95**: 627–33
- 36 Servin FS, Marchand-Maillet F, Desmonts JM. Influence of analgesic supplementation on the target propofol concentrations for anaesthesia with ‘Diprifusor’ TCI. *Anaesthesia* 1998; **53**(Suppl. 1): 72–6
- 37 Jinks SL, Carstens E, Antognini JF. Nitrous oxide-induced analgesia does not influence nitrous oxide’s immobilizing requirements. *Anesth Analg* 2009; **109**: 1111–6
- 38 Hans GA, Lauwick SM, Kaba A, et al. Intravenous lidocaine infusion reduces bispectral index-guided requirements of propofol only during surgical stimulation. *Br J Anaesth* 2010; **105**: 471–9
- 39 Gibbs NM, Weightman WM. Beyond effect size: consideration of the minimum effect size of interest in anesthesia trials. *Anesth Analg* 2012; **114**: 471–5
- 40 Richebe P, Rivat C, Creton C, et al. Nitrous oxide revisited: evidence for potent antihyperalgesic properties. *Anesthesiology* 2005; **103**: 845–54

Handling editor: M. M. R. F. Struys